Combination of thrombopoietin receptor agonists, immunosuppressants and intravenous immunoglobulin as treatment of severe refractory immune thrombocytopenia in adults and children

Sif Gudbrandsdottir; Emily Leven; Allison Imahiyerobo; Christina Soo Lee; James Bussel

doi:10.1111/bjh.16426

Combination of thrombopoietin receptor agonists, immunosuppressants and intravenous immunoglobulin as treatment of severe refractory immune thrombocytopenia in adults and children

Br J Haematol. 2020 Apr;189(2):e37-e40. doi: 10.1111/bjh.16426. Epub 2020 Feb 24.

Authors

Sif Gudbrandsdottir^{1

2

3}, Emily Leven^{1

4}, Allison Imahiyerobo^{1

5}, Christina Soo Lee^{1

6}, James Bussel¹

Affiliations

¹ Department of Pediatric Oncology/Hematology, New York Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA.
² Department of Hematology, Copenhagen University Hospital Roskilde, Roskilde, Denmark.
³ Institute for Inflammation Research, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
⁴ Icahn School of Medicine, Mount Sinai, NY, USA.
⁵ Department of Medicin, Columbia University Medical Centre, New York, NY, USA.
⁶ New York Medical College, New York, NY, USA.

PMID: 32096213
DOI: 10.1111/bjh.16426

No abstract available

Keywords: immunosuppressants; intravenous immunoglobulin G; primary immune thrombocytopenia; refractory disease; thrombopoietin-receptor agonists.

Publication types

Letter

MeSH terms

Adolescent
Adult
Aged
Child
Child, Preschool
Female
Humans
Immunoglobulins, Intravenous / pharmacology
Immunoglobulins, Intravenous / therapeutic use*
Immunosuppressive Agents / pharmacology
Immunosuppressive Agents / therapeutic use*
Infant
Male
Middle Aged
Purpura, Thrombocytopenic, Idiopathic / drug therapy*
Receptors, Thrombopoietin / agonists*
Young Adult

Substances

Immunoglobulins, Intravenous
Immunosuppressive Agents
Receptors, Thrombopoietin